You are here

Atorvastatin Versus Simvastatin In The Prevention Of Coronary Heart Disease (CHD) In Patients With Known CHD

Last updated on October 4, 2018

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Arhus C, , DK-8000 Denmark
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Cardiovascular Diseases
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0-80
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Previous myocardial infarction

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Women who are breast feeding or are pregnant

NCT00159835
Pfizer
Completed
Atorvastatin Versus Simvastatin In The Prevention Of Coronary Heart Disease (CHD) In Patients With Known CHD

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Psoriatic Arthritis, Psoriasis, Papulosquamous Skin Diseases
NCT00293709
All Genders
18+
Years
Muenchen,
Hypercholesterolemia, Dyslipidemias, Hyperlipidemias, Lipid Metabolism Disorders, Metabolic Diseases
NCT01435382
All Genders
18+
Years
Multiple Sites
Spinal Cord Diseases, Spinal Cord Injuries, Neuralgia, Pain
NCT01202227
All Genders
18+
Years
Multiple Sites
Psoriatic Arthritis, Psoriasis, Papulosquamous Skin Diseases
NCT00293722
All Genders
18+
Years
Toerwang-Samerberg,
Atorvastatin Versus Simvastatin In The Prevention Of Coronary Heart Disease (CHD) In Patients With Known CHD
Atorvastatin Compared With Simvastatin In The Prevention of CHD Morbidity And Mortality In Patients With CHD
To investigate whether a long-term strategy to lower LDL cholesterol with atorvastatin as much as possible will improve prognosis in CHD patients compared with a strategy reflecting current best clinical practice with simvastatin.
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Cardiovascular Diseases
  • Drug: atorvastatin
  • Drug: simvastatin
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
8600
March 2005
Not Provided

Inclusion Criteria:

  • Previous myocardial infarction

Exclusion Criteria:

  • Women who are breast feeding or are pregnant
Sexes Eligible for Study: All
up to 80 Years   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Denmark,   Finland,   Iceland,   Netherlands,   Norway,   Sweden
 
 
NCT00159835
ATV-N-98-001
A2581145
Not Provided
Not Provided
Not Provided
Not Provided
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
April 2015

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now